ADC Therapeutics Q3 Adj. EPS $(0.41) Beats $(0.63) Estimate, Sales $14.49M Miss $15.99M Estimate
ADC Therapeutics Q3 Adj. EPS $(0.41) Beats $(0.63) Estimate, Sales $14.49M Miss $15.99M Estimate
ADC Therapeutics第三季度调整后的每股收益（0.41美元）超过了美元（0.63美元）的预期，销售额1449万美元未达到预期的1599万美元
ADC Therapeutics (NYSE:ADCT) reported adjusted quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.63) by 34.92 percent. This is a 415.38 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $14.49 million which missed the analyst consensus estimate of $15.99 million by 9.36 percent. This is a 81.01 percent decrease over sales of $76.32 million the same period last year.
ADC Therapeutics（纽约证券交易所代码：ADCT）报告调整后的每股季度亏损为0.41美元（0.41美元），比分析师共识估计的0.63美元（0.63美元）高出34.92％。这比去年同期的每股收益0.13美元下降了415.38％。该公司公布的季度销售额为1449万美元，比分析师普遍估计的1,599万美元低9.36％。这比去年同期的7,632万美元的销售额下降了81.01％。
资讯热榜
更新时间